Email
Print
Primary Biliary Cholangitis (PBC) Treatment Market - Industry Analysis, Market Size, Share, Trends, Application Analysis, Growth And Forecast 2022-2027
Primary Biliary Cholangitis (PBC) Treatment Market Overview
Primary Biliary Cholangitis (PBC) Treatment Market size is estimated to reach $1,551.1 million by 2027, growing at a CAGR of 10.3% during the forecast period 2022-2027. Primary biliary cholangitis (PBC), formerly termed primary biliary cirrhosis, is a chronic ailment in which the bile ducts in the liver are gradually demolished. Bile is a liquid prepared in the liver. It assists with digestion and backs the absorption of some vitamins. It also encourages the body to do away with cholesterol, toxins and worn-out red blood cells. Primary Biliary Cholangitis (PBC) Treatment involves medicines and liver transplantation in serious cases. The traditional approach toward autoimmune disease diagnosis involves medications, steroids and immunosuppressants. These medicines can camouflage some symptoms for a time. The burgeoning phase of regenerative and stem cell therapies is set to drive the Primary Biliary Cholangitis (PBC) Treatment Market. The heightening R&D financing and the existence of a strong pipeline for autoimmune disease diagnosis, specifical diagnosis of primary biliary cholangitis are set to propel the growth of the Primary Biliary Cholangitis (PBC) Treatment Industry during the forecast period 2022-2027. This represents the Primary Biliary Cholangitis (PBC) Treatment Industry Outlook.
Primary Biliary Cholangitis (PBC) Treatment Market Report Coverage
The “Primary Biliary Cholangitis (PBC)
Treatment Market Report - Forecast (2022-2027)” by Industry ARC,
covers an in-depth analysis of the following segments in the Primary Biliary Cholangitis (PBC)
Treatment Market.
Key Takeaways
- Geographically, North America (Primary Biliary Cholangitis (PBC) Treatment market share) accounted for the highest revenue share in 2021 and it is poised to dominate the market over the period 2022-2027 owing to the increasing predominance of Primary Biliary Cholangitis (PBC) involving autoimmune disease diagnosis in the North American region.
- Primary Biliary Cholangitis (PBC) Treatment Market growth is being driven by the surging count of pipeline investigations to establish outstanding treatments for rare ailments like Primary Biliary Cholangitis (PBC) which may advance to cirrhosis or fibrosis. However, the dearth of awareness among the populace regarding the ailment and binding regulatory policies are some of the major factors hampering the growth of the Primary Biliary Cholangitis (PBC) Treatment Market.
- Primary Biliary Cholangitis (PBC) Treatment Market Detailed Analysis of the Strength, Weaknesses and Opportunities of the prominent players operating in the market will be provided in the Primary Biliary Cholangitis (PBC) Treatment Market report.
Primary Biliary Cholangitis (PBC) Treatment Market: Market Share (%) by Region, 2021
For More Details On this report - Request For Sample
Primary Biliary Cholangitis (PBC) Treatment Market Segment Analysis - by Type Of Treatment
The Primary Biliary Cholangitis
(PBC) Treatment Market based on the type of treatment can be further segmented into Drugs and Liver Transplantation. The Drugs Segment held the largest Primary
Biliary Cholangitis (PBC) Treatment market share in 2021. This growth is owing
to the surging application of medications like Ursodeoxycholic acid (UDCA) and Obeticholic
acid (Ocaliva) to slow the advancement of primary biliary cholangitis and avert
complexities. Investigations demonstrate that Obeticholic acid (Ocaliva) when
administered alone or integrated with ursodiol for 12 months may assist in enhancing
liver function and slow liver fibrosis. The typical application of Ursodeoxycholic acid
(UDCA) also termed ursodiol (Actigall, Urso) as the earliest medication is further
propelling the growth of the Drugs segment.
Furthermore, the Liver Transplantation segment is estimated to grow with
the fastest CAGR of 11.1% during the forecast period 2022-2027 owing to the
increasing application of liver transplantation for patients with progressive primary
biliary cirrhosis and primary sclerosing cholangitis attributed to its great
effectiveness.
Primary Biliary Cholangitis (PBC) Treatment Market Segment Analysis - by Distribution Channel
The Primary Biliary
Cholangitis (PBC) Treatment Market based on distribution channels can be further
segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. The Online
Pharmacies Segment held the
largest Primary Biliary Cholangitis (PBC) Treatment market share in
2021. This growth is owing to the increasing application of online
pharmacies by patients with primary biliary cholangitis for the purchase of
medications like Ursodeoxycholic Acid and Ocaliva (obeticholic acid) amidst the
COVID-19 (Coronavirus) pandemic. The surging benefits of online pharmacies like
a superior price range, convenience and effortless accessibility are further
propelling the growth of this segment.
Furthermore, the Hospital Pharmacies segment
is estimated to grow with the fastest CAGR of 11.3% during the forecast period 2022-2027 owing to the expanding
inclination of patients toward hospital pharmacies for immediate purchase of
medications for the treatment of primary biliary cholangitis subsequent to the
prescription by the physician in hospitals as the world returns to normal after
the fight against the COVID-19 (Coronavirus) pandemic.
Primary Biliary Cholangitis (PBC) Treatment Market Segment Analysis - by Geography
The Primary Biliary
Cholangitis (PBC) Treatment Market based on geography can be further segmented
into North America, Europe, Asia-Pacific, South America and the Rest of the World. North
America (Primary Biliary Cholangitis (PBC) Treatment Market) held the largest Primary Biliary Cholangitis (PBC) Treatment market share with 35% of the overall market in
2021. The growth of this region is owing to the well-entrenched
healthcare infrastructure in the North American region. The increasing predominance of primary
biliary cirrhosis resulting in greater demand for therapeutics, the
existence of key players like Bristol-Myers Squibb Company in the U.S. and current
product launches are further propelling the growth of the Primary Biliary
Cholangitis (PBC) Treatment Industry, thereby contributing to the Primary
Biliary Cholangitis (PBC) Treatment Industry Outlook, in the North American
region.
Furthermore, the Asia-Pacific region is estimated to be the region with the fastest CAGR over the forecast period 2022-2027. This growth is owing to factors like the surging pervasiveness of primary biliary cholangitis in countries like Japan in the Asia-Pacific region. The expanding awareness connected with rare diseases, the emerging healthcare infrastructure and the government backing for new treatment against autoimmune disease diagnosis is further fuelling the progress of the Primary Biliary Cholangitis (PBC) Treatment Market in the Asia-Pacific region.
Primary Biliary Cholangitis (PBC) Treatment Market Drivers
Novel Developments in the Treatment of Primary Biliary Cholangitis are Projected to Drive the Growth of Primary Biliary Cholangitis (PBC) Treatment Market:
As per www.autoimmuneinstitute.org, on the whole, 78% of people influenced by autoimmune disease are female. As per my.clevelandclinic.org, 1 in 15 people in the U.S. endure an autoimmune disease and one million people in the U.S. bear lupus and 1.4 million put up with Crohn’s disease or ulcerative colitis. Primary biliary cholangitis (PBC) brings about incessant and determined cholestasis in the liver, finally leading to cirrhosis and hepatic failure without suitable treatment. PBC principally develops in middle-aged women, however, it is also typical in young women and men. Primary biliary cholangitis (PBC) is an incessant autoimmune cholestatic liver disease that principally influences women in early to middle age. It is usually connected with autoantibodies to mitochondrial antigens and leads to immune-mediated devastation of tiny and medium-sized intrahepatic bile ducts resulting in cholestasis and hepatic fibrosis and can advance to cirrhosis or hepatic failure and in certain cases, hepatocellular carcinoma. Currently, liver transplantation is the most efficient treatment modality for PBC patients with end-stage liver ailment. These kinds of novel developments in the treatment of Primary Biliary Cholangitis are therefore fuelling the growth of the Primary Biliary Cholangitis (PBC) Treatment Market during the forecast period 2022-2027.
Autoimmune Disease Diagnosis of Primary Biliary Cholangitis (PBC) is Expected to Boost the Growth of the Primary Biliary Cholangitis (PBC) Treatment Industry:
Physicians diagnose primary biliary cholangitis on the basis of medical and family history, a physical exam and the outcomes of medical tests. Physicians may suggest blood tests like Anti-mitochondrial antibodies (AMA) and Liver tests. Anti-mitochondrial antibodies are discovered in the blood of around 95% of people with primary biliary cholangitis. Liver tests can demonstrate abnormal liver enzyme levels, which may be a sign of injury in the liver or biliary tract. Higher-than-normal levels of the liver enzyme alkaline phosphatase happen in people with ailments that devastate or obstruct the bile ducts, like primary biliary cholangitis. People with primary biliary cholangitis can have higher-than-normal cholesterol levels. The physician can utilize imaging tests like x-rays and ultrasounds to assist in diagnosing primary biliary cholangitis by ruling out additional causes of damage to bile ducts like gallstones, bile duct strictures and tumors. At the time of a liver biopsy, a physician will take tiny bits of tissue from the liver. The autoimmune disease diagnosis of Primary Biliary Cholangitis (PBC) is therefore driving the growth of the Primary Biliary Cholangitis (PBC) Treatment Industry, thereby contributing to the Primary Biliary Cholangitis (PBC) Treatment Industry Outlook during the forecast period 2022-2027.
Primary Biliary Cholangitis (PBC) Treatment Market Challenge
Complexities from Primary Biliary Cholangitis (PBC) are Hampering the Growth of the Primary Biliary Cholangitis (PBC) Treatment Market:
Progressive liver injury termed cirrhosis not only influences the capability of the liver to carry out its tasks but also raises the hazards of liver cancer. Cirrhosis patients may also endure portal hypertension. A principal issue with Primary Biliary Cholangitis (PBC) is cholestasis - when bile flow halts - inside the liver, which brings about the liver issues of PBC. However, cholestasis also results in additional issues when bile does not advance to additional portions of the body that require it to operate correctly, like the intestine and gallbladder. As liver cirrhosis is brought about by PBC advances, it can result in an enlarged spleen. Around 30% of people with PBC endure gentle alterations in bone density termed osteopenia. Another 10% endure considerable bone density losses sufficient to bring about osteoporosis. It is possible that people with PBC endure bone alterations owing to cholestasis connected with PBC which means that there is reduced bile in the intestines. These issues are thus hampering the growth of the Primary Biliary Cholangitis (PBC) Treatment Market.
Primary Biliary Cholangitis (PBC) Treatment Industry Outlook
Novel product launches, product innovations, geographical expansions and R&D financing are key strategies adopted by players in the Primary Biliary Cholangitis (PBC) Treatment Market. The top 10 companies in the Primary Biliary Cholangitis (PBC) Treatment market are:
- Novartis AG
- Actavis Inc.
- Bristol-Myers Squibb Company
- NGM Biopharmaceuticals
- Lumena Pharmaceuticals Inc. Terumo Corporation
- Siedco Pharmaceutical Co.
- Teva Pharmaceuticals Inc.
- Intercept Pharmaceuticals Inc.
- Glenmark Pharmaceuticals
- Mylan Inc.
Recent Developments
- In June 2022, Intercept Pharmaceuticals Inc., declared outcomes from two investigations planned to assess clinical results in patients with PBC on Ocaliva (obeticholic acid or OCA): COBALT, a Phase 3b/4 confirmatory clinical results investigation and HEROES-US, one of two HEROES real-world investigations.
- In May 2022, Intercept Pharmaceuticals, Inc. declared that the earliest patient has been dosed in a Phase 2 investigation assessing a fixed-dose combination of obeticholic acid (OCA) and bezafibrate (BZF) for the treatment of patients with primary biliary cholangitis (PBC) who have not accomplished a sufficient biochemical response to ursodeoxycholic acid. The double-blind, randomized, active-controlled, parallel-group investigation will assess the decrease in alkaline phosphatase (ALP) over 12 weeks, succeeded by a long-term safety extension.
- In May 2022, Intercept Pharmaceuticals, Inc. declared that it has entered into an agreement to market to Advanz Pharma, a pharmaceutical firm with a strategic focus on specialty and hospital pharmaceuticals in Europe, some foreign subsidiaries and rights concerning Intercept’s international operations, inclusive of a license to commercialize Ocaliva® (obeticholic acid) external of the U.S.
Relevant Reports:
Report Code: HCR 0256
Report Code: HCR 0268
Report Code: HCR 0284
For more Lifesciences and Healthcare Market reports, please click here